文献速递心境障碍

米诺环素与塞来昔布辅助治疗双相抑郁的多中心析因随机对照试验

Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial.
PubMed 文献 · Lancet Psychiatry · 2020-05-20

该双盲、12周、随机、安慰剂对照试验在巴基斯坦4家门诊精神科诊所纳入266例DSM-5双相障碍I或II型伴重性抑郁发作的成人患者,采用2×2析因设计评估米诺环素或塞来昔布辅助治疗的疗效。结果显示,12周时HAMD-17评分在四组均下降,但米诺环素与塞来昔布的主效应均不显著优于安慰剂,未发现辅助抗炎药治疗双相抑郁有效的证据。

要点

  • 米诺环素辅助治疗双相抑郁的HAMD-17改善与安慰剂无显著差异。
  • 塞来昔布辅助治疗双相抑郁的HAMD-17改善与安慰剂无显著差异。
  • 四组严重不良事件率无差异,31例出现躁狂转换。

核心结论

  • 未发现米诺环素或塞来昔布辅助治疗双相抑郁优于安慰剂的证据。
  • 该大型试验对辅助抗炎药急性期治疗双相抑郁的潜在获益提出质疑。

研究设计与样本

  • 双盲、12周、随机、安慰剂对照试验,在巴基斯坦4家门诊精神科诊所进行。
  • 纳入266例18-65岁DSM-5双相障碍I或II型伴重性抑郁发作的成人患者。
  • 采用2×2析因设计,按1:1:1:1随机分配至米诺环素+塞来昔布、米诺环素+安慰剂、塞来昔布+安慰剂或双安慰剂组。
  • 主要结局为基线至第12周HAMD-17评分平均变化,在意向治疗人群中分析。

主要发现

  • 严重不良事件率组间无差异:31例出现躁狂转换,2例自伤,1例死于机动车事故。

关键数值与推荐

  • 主要结局为HAMD-17评分从基线至第12周的平均变化。

临床怎么用

  • 不推荐将米诺环素或塞来昔布作为双相抑郁的常规辅助治疗。
  • 临床决策应基于现有循证治疗,而非抗炎药物的潜在获益。

局限性

  • 原文未报告针对该试验设计局限性的具体说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several small studies suggest that the adjunctive use of anti-inflammatory agents might improve depressive symptoms in bipolar disorder. However, there are few well designed, appropriately powered clinical trials assessing the efficacy of these novel treatment strategies. We aimed to assess the efficacy of adjunctive minocycline or celecoxib in this setting. METHODS: This double-blind, 12-week, randomised, placebo-controlled trial was done in four outpatient psychiatric clinics in Pakistan. Eligible participants were adults (aged 18-65 years) with DSM-5 bipolar disorder (type I or II) and a major depressive episode. In a 2 × 2 factorial design, participants were randomly assigned (1:1:1:1) to receive either active minocycline plus active celecoxib, active minocycline plus placebo celecoxib, placebo minocycline plus active celecoxib, or placebo minocycline plus placebo celecoxib. The primary outcome was the mean change from baseline to week 12 in score on the 17-item Hamilton Depression Rating Scale (HAMD-17), assessed in all randomised participants (missing data were imputed and assumed to be missing at random). The trial was registered with ClinicalTrials.gov, NCT02703363. FINDINGS: 266 (17%) of 1542 patients assessed between May 1, 2016, and March 31, 2019, were randomly assigned to receive minocycline plus celecoxib (n=68), minocycline plus placebo (n=66), celecoxib plus placebo (n=66), or placebo plus placebo (n=66). From baseline to week 12, depressive symptoms as per HAMD-17 reduced in all four groups (from 24·5-25·2 to 11·3-12·8), but these reductions did not differ significantly between the groups. In terms of main effects, reductions in HAMD-17 did not differ for patients treated with minocycline (mean adjusted difference vs non-minocycline 1·48 [95% CI -0·41 to 3·36]; p=0·123) or for celecoxib (mean adjusted difference vs non-celecoxib -0·74 [-2·61 to 1·14]; p=0·443). Rates of serious adverse effects did not differ between groups (31 participants had a manic switch, two self-harmed, and one died in a motor vehicle accident). INTERPRETATION: We found no evidence that minocycline or celecoxib was superior to placebo for the treatment of bipolar depression. This large trial casts doubt on the potential therapeutic benefits of adjunctive anti-inflammatory drugs for the acute management of bipolar depression. FUNDING: Stanley Medical Research Institute.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Husain MI, Chaudhry IB, Khoso AB, et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry. 2020. PMID: 32445690. doi:10.1016/S2215-0366(20)30138-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。